About: Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
Sector: Healthcare
Industry: Biotechnology
Latest price: $2.91 (-9.91%)
NKTXNASDAQNkarta Inc
Nkarta Inc share price
NKTX price activity
Last Price
$2.910
Change (24hr)
-0.32 USD (-9.91%)
Volume
781.36K
Volume (4w avg)
-
Open
$3.19
Day Range
$2.86 - $3.20
Previous Close
$3.23
Last Trade
09 Sep, 8:00 pm GMT+0
Delayed
09 Sep, 8:00 pm GMT+0
NKTX price performance
Delayed
09 Sep, 8:00 pm GMT+0
NKTX Market Signals